Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?

By Josh Enomoto, InvestorPlace Contributor

With Rocket Pharmaceuticals reaching a Phase II agreement with the FDA, RCKT stock soared, though some concerns linger.

Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm

By Josh Enomoto, InvestorPlace Contributor

Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony.

3 Uranium Stocks to Buy as Nuclear Energy Regains Popularity

By Josh Enomoto, InvestorPlace Contributor

With investors recognizing the viability of nuclear energy, these risky but compelling uranium stocks make sense for gamblers.

The 3 Most Undervalued Meme Stocks to Buy in September 2023

By Josh Enomoto, InvestorPlace Contributor

While betting alongside the whims of the internet can be dangerous, these undervalued meme stocks could be enticing for some.

7 Cryptos to Watch as the Blockchain Slogs Through

By Josh Enomoto, InvestorPlace Contributor

With traders across the blockchain ecosystem taking precautions, investors need to be prudent about their exposure to cryptos.

Load More